US2020369749A1PendingUtilityA1
Immuno-based botulinum toxin serotype a activity assays
Est. expiryMar 14, 2028(~1.7 yrs left)· nominal 20-yr term from priority
Inventors:Ester Fernandez-SalasJoanne WangPatton E. GarayLina S. WongD. Dianne HodgesKei Rogers Aoki
G01N 2333/952G01N 2333/33C07K 2317/77G01N 33/56911G01N 2333/705C07K 2317/565C07K 2317/56C07K 16/12A61P 25/00A61P 27/02G01N 33/5014A61P 25/04C12Q 1/37G01N 33/569C07K 2317/92G01N 33/566G01N 33/6854C07K 16/1282A61P 25/08C07K 14/33C07K 14/10C07K 2317/34A61P 25/02
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P 1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P 1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing α-BoNT/A antibodies.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated α-SNAP-25 antibody, wherein the isolated α-SNAP-25 antibody specifically binds to the peptide of SEQ ID NO:38, and wherein the isolated α-SNAP-25 antibody comprises a heavy chain variable region comprising complementary determining regions (CDRs) comprising the amino acid sequences of at least one of SEQ ID NOs: 93, 96, and 100 and a light chain variable region comprising CDRs comprising the amino acid sequences of at least one of SEQ ID NOs: 105, 110 and 115; or a heavy chain variable region comprising complementary determining regions (CDRs) comprising the amino acid sequences of at least one of SEQ ID NOs: 95, 99, and 101 and a light chain variable region comprising CDRs comprising the amino acid sequences of at least one of SEQ ID NOs: 103, 108 and 113.
2 . The isolated α-SNAP-25 antibody of claim 1 , comprising a heavy chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NO: 95 (CDR1), SEQ ID NO: 99 (CDR2), and SEQ ID NO: 101 (CDR3) and a light chain variable region comprising CDRs comprising the amino acid sequences of SEQ ID NO: 103 (CDR1), SEQ ID NO: 108 (CDR2), and SEQ ID NO: 113 (CDR3).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.